Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06369597
Other study ID # Robot2024
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 15, 2024
Est. completion date March 31, 2025

Study information

Verified date April 2024
Source Sun Yat-sen University
Contact Kuang Ming, PhD
Phone 008687755766
Email kuangm@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized controlled trial that will be preceded by a safety trial focusing on the safety and efficacy of robotic telesurgery. The hypothesis is that robotic telesurgery has a non-inferior primary endpoint event rate to local laparoscopic surgery.


Description:

First, a safety run-in trial for robotic telesurgery will be conducted and evaluated according to "3+3 design". At least 3 patients of each cancer type (including liver cancer,renal cancer and rectal cancer) will be enrolled for robotic telesurgery. If there is a tumor type for which the prior safety trial is terminated, the subsequent randomized controlled trial will not include patients of that type. Second, after passing the safety run-in trial, a randomized controlled trial will be performed. New patients with each cancer type who met the enrollment criteria will be randomly assigned to either the laparoscopic surgery group(control group) or the robotic telesurgery group (intervention group) (84 patients in each group, 168 patients in total) in a 1:1 two-group parallel design.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 177
Est. completion date March 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Liver Cancer: 1. Age 18 - 75 years. 2. Clinical diagnosis of primary hepatocellular carcinoma or benign tumor such as hepatic adenoma. 3. Patients with hepatocellular carcinoma (BCLC stage 0-B) who were considered suitable for laparoscopic or robotic partial hepatectomy after MDT discussion, or benign tumor such as liver adenoma. 4. ECOG score 0 ~ 1. 5. Child-Pugh score 5 ~ 7. - Renal cancer: 1. Age 18 - 75 years old. 2. Clinical diagnosis of renal cancer (cT1-T2) or benign tumor such as renal malformation tumor. 3. Patients with benign tumors such as renal cancer (cT1-T2) or renal staggered tumor who were considered amenable to laparoscopic or robotic partial nephrectomy after MDT discussion. 4. ECOG score 0 ~ 1. - Rectal cancer: 1. Age 18 - 75 years old. 2. Clinical diagnosis of rectal cancer (Stage I-III). 3. Patients with primary rectal cancer who are considered amenable to laparoscopic or robotic radical rectal adenocarcinoma surgery after MDT discussion. 4. ECOG score 0 ~ 1. Exclusion Criteria: - Liver Cancer: 1. Pregnant and lactating women. 2. Combination of other malignant tumors or other malignant tumors within 5 years before enrollment. 3. Recipients of allogeneic organ transplantation. 4. Severe dysfunction of heart, lung, kidney and other organs. - Renal cancer: 1. Pregnant and lactating women. 2. Lymph node metastasis, metastasis to other organs, previous surgical history of renal cancer, or any situation that cannot accept general anesthesia. 3. Combination of other malignant tumors or combination of other malignant tumors within 5 years prior to enrollment. 4. allogeneic organ transplant recipients. 5. Severe dysfunction of heart, lungs, kidneys and other organs. - Rectal cancer: 1. patients with stage IV or complicated disease and emergency surgery. 2. Pregnant and lactating women. 3. Combination of other malignant tumors or combination of other malignant tumors within 5 years before enrollment. 4. Allogeneic organ transplant recipients. 5. Severe dysfunction of heart, lung, kidney and other organs.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Robotic telesurgery
Telesurgery by domestic surgical robot
Laparoscopic surgery
Local laparoscopic surgery

Locations

Country Name City State
China First Affiliated Hospital, Sun Yat-Sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Surgical complication Overall complication events within 30 days of surgery or intraoperative emergency intermediate open surgery events as defined by the Clavin-Dindo grading system One month after surgery
Secondary Surgical time (min) Total time from the start of surgery after robotic or laparoscopic installation to the end of incision closure and the surgeon's operating time. One month after surgery
Secondary Intraoperative blood loss (mL) Total bleeding from the start of surgery to the end of incision suturing. One month after surgery
Secondary Postoperative hospitalization days Number of days from the day of surgery to the day of discharge. One month after surgery
Secondary Physician satisfaction A NASA-TLX quantification form was completed by the physician postoperatively. One month after surgery
Secondary Remote metrics Record data related to network transmission end-to-end latency time, jitter, and frame loss. One month after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A